Outcome of Board Meeting held on 13th February 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.8 pts more than Nifty Microcap 250 and 3.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kabra Drugs Ltd's board approved unaudited financial results for the quarter and nine months ended 31st December 2025. Q3 FY26 revenue from operations jumped to Rs 3,042 lakhs from Rs 715 lakhs in Q3 FY25 (~325% YoY growth), and net profit swung to Rs 256.65 lakhs from a loss of Rs 49.98 lakhs in the year-ago quarter. For the nine-month period, revenue was Rs 5,733.40 lakhs with net profit of Rs 390.34 lakhs, against a net loss of Rs 147.85 lakhs in the prior-year period. EPS for Q3 FY26 stood at Rs 1.08 versus Rs (0.21) loss per share in Q3 FY25. A prior-period tax reversal of Rs 36.81 lakhs, arising from the company switching to the new tax regime, boosted Q3 net profit. The statutory auditors (PPNAnd Company) issued a clean limited review report with no qualifications.
A sharp revenue and profit turnaround from loss-making to solidly profitable is materially positive for shareholders and likely supportive of the stock. However, the magnitude of the swing, the one-time tax adjustment, and the lack of prior-period comparability warrant close scrutiny on sustainability of the new earnings trajectory.